A NETWORK META-ANALYSIS TO EVALUATE THE EFFICACY OF BARICITINIB AND OTHER TREATMENTS OF RHEUMATOID ARTHRITIS IN PATIENTS WHO ARE INADEQUATE RESPONDERS TO METHOTREXATE
Author(s)
Smolen JS1, Emery P2, Dudler J3, Zerbini C4, Walid F5, Nicolay C6, de La Torre I7, Burmester G8
1Medical University of Vienna, Vienna, Austria, 2NIHR Leeds Biomedical Research Centre, Leeds, UK, 3HFR Fribourg - Hôpital cantonal, Fribourg, Switzerland, 4Centro Paulista de Investigação Clínica, Sao Paulo, Brazil, 5Eli Lilly & Company, Windlesham, UK, 6Lilly Deutschland GmbH, Bad Homburg, Germany, 7Eli Lilly and Company, indianapolis, IN, USA, 8Charité - University Medicine Berlin, Berlin, Germany
OBJECTIVES: To assess the comparative effectiveness of baricitinib (BARI) 4-mg (background MTX) (oral, JAK 1/2 inhibitor) and other targeted synthetic/biologic disease modifying anti-rheumatic drugs in moderate-to-severe rheumatoid arthritis (RA) patients with inadequate response to methotrexate (MTX-IR). METHODS: A systematic literature review (SLR) of randomized controlled trials (RCTs-Phase 3) of interventions of interest was conducted (1999 to 2017) in Medline, Medline In-Process, Embase, Biosciences Information Service, the Cochrane Library, and trials registers. Network meta-analyses (NMAs) of RCTs reporting the American College of Rheumatology (ACR) response data were conducted using Bayesian mixed-treatment comparisons. Here we present main results for the 24-week (+/-4) timepoint (fixed effects simultaneous models). RESULTS: CONCLUSIONS: The comparative analyses support BARI as an efficacious treatment option for moderate-to-severe RA patients with inadequate response to MTX.
Conference/Value in Health Info
2018-11, ISPOR Europe 2018, Barcelona, Spain
Value in Health, Vol. 21, S3 (October 2018)
Code
PMS5
Topic
Clinical Outcomes
Topic Subcategory
Comparative Effectiveness or Efficacy
Disease
Musculoskeletal Disorders